Fundraising Fox

A2 Biotherapeutics

Agoura Hills, US · Founded 2017 · Delaware corporation · 4 known investors

A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications. The company targets cancer and other serious diseases, advancing its cell therapies through clinical trials.

BiotechHealthtech

Founders & leadership

A2 Biotherapeutics was founded in 2017 by C. Alexander Kamb.

CA
C. Alexander KambinFounder
SF
Scott ForakerNamed on SEC filing
MB
Madhavan BalachandranNamed on SEC filing
MG
Michael GalloNamed on SEC filing

Board

SASrini Akkaraju
Srini Akkarajuin𝕏Board directorFounder and Managing Partner at Samsara BioCapital
DG
David GoeddelBoard director
HS
Helen S. KimBoard director
JLJakob Loven
Jakob Lovenin𝕏Board directorPartner at Nextech Invest

Investors · 4

Nextech InvestZurich · $648K – $3.2M
Vida VenturesLos Angeles
Samsara BioCapitalreported · 3 sourcesPalo Altovia Srini Akkaraju · board
The Column Groupreported · 3 sourcesSan Francisco · $30Mvia David Goeddel · board

Funding

SEC filings, press & company announcements

$223.1M disclosed across 3 rounds · 2020–2025

▶$71.6MraisedDec 2022 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Madhavan BalachandranDirector
  • Helen S. KimDirector
  • Scott ForakerExecutive Officer, Director
  • David LucasExecutive Officer
  • Susan L. KelleyDirector
  • Srini AkkarajuDirector
  • Jakob LovenDirector
  • William GoExecutive Officer
  • Thomas LeungExecutive Officer
  • Alexander KambExecutive Officer, Director
  • David GoeddelDirector
Offering amount
$71.6M
Amount sold
$71.6M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$71.5MraisedOct 2020 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott ForakerExecutive Officer, Director
  • Srini AkkarajuDirector
  • Madhavan BalachandranDirector
  • Michael GalloDirector
  • David GoeddelDirector
  • C. Alexander KambDirector
  • Helen S. KimDirector
  • Jakob LovenDirector
Offering amount
$71.5M
Amount sold
$71.5M
First sale
Sep 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

A2 Biotherapeutics: $80 Million (Series C) Raised For Advancing Clinical Development Of Precision Cell Therapiespulse2.com · Jan 2025A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours - Pharmaceutical Technologypharmaceutical-technology.com · Jan 2025A2 Biotherapeutics Raises $80M Series C Fundingfinsmes.com · Jan 2025Scoop: A2 Biotherapeutics raises $62M for solid tumor cell therapiesendpoints.news · Dec 2022A2 Biotherapeutics Closes $71.5M Series B Funding - FinSMEsfinsmes.com · Oct 2020A2 Biotherapeutics Closes $71.5M Series B To Begin Clinical Development Of Its Potentially Transformative Selective Tumor Cell Therapeutics - BioSpacebiospace.com · Oct 2020

Frequently asked questions

What does A2 Biotherapeutics do?
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications. The company targets cancer and other serious diseases, advancing its cell therapies through clinical trials.
Who founded A2 Biotherapeutics?
A2 Biotherapeutics was founded by C. Alexander Kamb in 2017.
Who are A2 Biotherapeutics's investors?
A2 Biotherapeutics's investors include Nextech Invest, Vida Ventures, Samsara BioCapital, The Column Group.
How much funding has A2 Biotherapeutics raised?
A2 Biotherapeutics has disclosed $223.1M raised across 3 rounds.
Where is A2 Biotherapeutics headquartered?
A2 Biotherapeutics is headquartered in Agoura Hills, US.